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Abstract 1H-NMR spectroscopy and analytical ultracentrifu- through interactions that involve the NH2-terminal regions 
gation studies reveal that monocyte chemoattractant protein-3 of the two subunits [11-13]. In addition, PF-4 and NAP-2, 
(MCP-3) is a monomer. NMR solution structure shows that which are CXC chemokines, form tetramers and show both 
MCP-3 adopts an oJ13 fold similar to what is observed in IL-8 and RANTES type interfaces [14,15]. 
structures of other known chemokines. However, MCP-3 is In addition, the two subfamilies are functionally distinct. 
unique in that it does not show a propensity to form dimers. The The CXC chemokines are predominantly neutrophil chemoat- 
closely related chemokines MCP-1 and MCP-2 show a tractants, whereas the CC chemokines attract other cell types, 
monomer-dimer equilibrium in sedimentation equilibrium studies but not neutrophils. MCP-1, MCP-2 and MCP-3 share con- 
(,--0.2-2 mglml). As these proteins are present at nanomolar siderable sequence similarity (60 71%) (Fig. 1). Despite this, 
concentrations in vivo, the results suggest that they are functional differences between them are apparent. MCP-3 
monomeric at functional concentrations and that the monomer 
is the functionally significant form of MCP-1, MCP-2 and stimulates eosinophils in addition to other cell types, whereas 
MCP-3. MCP-1 does not affect eosinophils [4]. MCP-2 appears to have 
similar activities to MCP-3, but is less potent than MCP-3 
Key words." Monocyte chemotactic protein; NMR;  Solution [16]. In addition other differences including intracellular sig- 
structure; Monomer-dimer naling mechanisms have been reported [17]. 
The multiple functional activities of MCP-3 suggest hat 
comparison of its structure with other chemokines, as well 
as its structure-activity relationships, will be of importance 
1. Introduction for understanding its mechanism of action in inflammation. 
Here we compare the quaternary structure of the three MCP 
Monocyte chemoattractant protein (MCP)-I [1], MCP-2 proteins: MCP-1, MCP-2 and MCP-3; and furthermore de- 
and MCP-3 [2,3] are members of the family of chemoattrac- scribe the 1H-NMR solution structure of MCP-3 which re- 
tant cytokines (chemokines). Chemokines timulate the migra- veals that it is a monomer. The results are discussed in terms 
tion and accumulation of various types of white blood cells of their implications for the structure and functions of the 
and are divided into two subfamilies according to the position chemokine family. 
of the first two cysteine residues [4,5]. For the CXC chemo- 
kines, e.g. interleukin 8 (IL-8), the first two cysteines are sep- 2. Materials and methods 
arated by one residue, whereas for the CC chemokines, in- 
cluding MCP-1, MCP-2, MCP-3, RANTES and MIP-113, the All proteins were synthesized, purified and characterized as de- 
first two cysteines are adjacent. The structures of a number of scribed previously [18]. The synthesis was accomplished by automated 
chemokines have been solved by NMR and X-ray crystallog- solid-phase synthesis (Applied Biosystems Model 430A) using the t- 
butyloxycarbonyl and benzyl protection strategy, deprotection with 
raphy methods and all show a similar structural topology hydrogen fluoride, and then folding by air oxidation and purification 
consisting of 3 anti-parallel 13 strands and an overlying by reverse-phase HPLC. Purity and the correctness of the product 
COOH-terminal ct helix [6]. Whilst CXC chemokines, such were assessed by reverse-phase HPLC and mass spectrometry. The 
as IL-8 and MGSA, dimerize by formation of a central six samples for NMR were prepared by dissolving the lyophilized protein 
stranded 13 sheet [7-10], the CC chemokines, such as MIP-113 in either 90% H2O110% D20 or 99.9% D20 and the pH was adjusted 
to 5.10 + 0.05 (glass electrode, uncorrected) with concentrated NaOD. 
and RANTES, dimerize in an end on end configuration Sedimentation equilibrium studies were carried out on a Beckman 
Spinco Model E analytical ultracentrifuge using Raleigh interference 
optics. The average molecular weights (Mav) from sedimentation equi- 
*Corresponding author. Fax: (1) (403) 492-1473. librium runs were calculated using the following equation: 
1present address. Structural Biology Center, Korea Institute of Science M~v - 2RT d(ln C) (1) 
and Technology, Seoul 130-650, South Korea. (1-~)p) t-02d(r2) 
Abbreviations." IL-8, interleukin-8; MCP, monocyte chemoattractant where R is the universal gas constant and is equal to 8.314× 107 erg/ 
protein; MGSA, melanoma growth stimulatory activity; MIP-1[3, mol per K, T is the temperature in K, P is the solvent density which 
macrophage inhibitory protein-l[3; NAP-2, neutrophil activating was calculated to be 1.005, co is the angular velocity (rpm×2~60) in
peptide-2; PF-4, platelet factor-4; DQF-COSY, double quantum rad/s, ~ is the partial specific volume of the protein (calculated from 
filtered correlation spectroscopy; NOE, nuclear Overhauser effect; the amino acid composition), and C is concentration in units of mg/ 
NOESY, NOE spectroscopy; RANTES, regulated on activation ml. 
normal T cell expressed; HPLC, high-performance liquid chromatog- All 1H-NMR experiments were performed on a Varian Unity 600 
raphy; RMS, root-mean-square NMR spectrometer. Standard pulse sequences were employed for res- 
0014-5793196l$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
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45 50 [ 55 60 65 70 75 
MCP-1 V I F K T I V A K E I C A D P K Q KW V Q D S M D H L D K Q T Q T P K T 
MCP-2  . . . . .  K R G - - V . . . . .  E R - R - K - - - Q I F - N L - P 
MCP-3 . . . . .  K L D . . . . . . .  T Q . . . . .  F - K . . . .  K . . . . .  L 
Fig. 1. Alignment of the primary amino acid sequence of MCP-1, MCP-2 and MCP-3. Disulfide bonds between conserved cysteines are indi- 
cated. 
onance assignments: PECOSY [19], DQF-COSY [20], TOCSY [21] is very close to the actual MW of 8957, indicating that MCP-3 
and NOESY [22]. TOCSY spectra were acquired with mixing times is a monomer.  For  MCP-1 (MW 8685) and MCP-2 (MW 
of 45 and 55 ms and NOESY spectra with mixing times of 70 and 150 
ms. All spectra were recorded in phase sensitive mode [23] and were 8915), the sedimentation profile is not linear. This is indicative 
referenced to externally added DSS. of the presence of higher order species and the calculated MW 
1H-NMR relaxation rates (R2=l/T2) were measured using the Carr- values (~ 11 000 and ,~ 13 700 for MCP-1 and MCP-2, re- 
Purcell-Merboom-Gill spin-echo pulse sequence [24]. The 1H-NMR spectively) indicate a distribution between monomers and di- 
relaxation time T2 for methyl protons is dependent on the rotation 
correlation time xc by the equation mers in the concentrat ion range of these experiments (,~ 0.2 -  
 0mg,m,  
_ = The amino acid Val 6° is conserved among MCP-1, MCP-2, 
T2 (m- l )  3xc + 1 + ¢02ox 2 1 + 4¢0o2x  J and MCP-3 and is expected to be in the similar environment 
(2) given the high sequence homology (Fig. 1). NMR relaxation 
where h is Plank's constant, 7 is the gyromagnetic ratio, r is the rates (R2) for the protons of the upfield CTH3 groups of Val 6° 
distance between two methyl protons, xc is the overall rotational cor- of these proteins were measured in order to calculate the 
relation time, m is the number of protons, 0 is 90 ° for a CH3 group, rotational correlation time (xc) (Fig. 3). The calculated T2 
COo is the spectrometer frequency, and internal rotation of the CH3 values for MCP-1 and MCP-2 (0.023, 0.021 s, respectively) 
group is assumed to be rapid [25]. Upon substitution for the known 
constants and assuming (¢0oZo) 2 >> 1 in Eq. 2 gives are shorter than those for MCP-3 (0.038 s) indicating that 
MCP-1 and MCP-2 have relatively higher molecular weights 
R2 = 1/T2 = ~xc (3) 
where ~.=3.75 ×109 s -2. The Stokes-Einstein equation indicates that ~c 
and hence R2 is proportional to the molecular weight for spherical 
proteins. Typically, for a molecular weight (MW) of 10000, % is 
~5× 10 -9 S at 25°C in H20 [26]. ," * 
NOE intensities for structure calculations were measured from the • ." • • 
150 ms NOESY spectrum by volume integration, and were converted ," ." • • 
into distances. The distance restraints were divided into 3 groups with • ," • 
ranges of 1.8-2.7, 1.8-3.5, and 2.3 5.0 ,~ and pseudoatoms are cor- •• ," • • 
rected appropriately. Structures were calculated using the hybrid dis- in c • == • • Mera 
tance geometry-dynamical simulated annealing program X-PLOR , ,  • • • MCP-2 
[27]. A total of 214 long-range (li--jl-->5) NOEs, 66 medium-range , , -  
(2-<1i-fl<-4) NOEs, 178 sequential NOEs, and 474 intra-residue • ".•: 
MCP-3 
NOEs were used for structure calculations. In addition, 58 ~ re- •• • • 
straints, 25 ~ restraints, 5 ~1 restraints and 16 backbone hydrogen , • • 
bond restraints were added at the later stage of structure calculations. 
3. Resu l ts  35000 36600 37000 38000 39000 
r20)2 
Sedimentation equil ibrium ultracentrifugation studies of 
Fig. 2. Average molecular weight determination by sedimentation 
MCP-1, MCP-2, and MCP-3 were carried out to assess equilibrium of MCP-1, MCP-2 and MCP-3. Plots of In C vs. r2(0 2 
whether they are monomers or form higher order quaternary are shown, where C is the concentration and r is the distance from 
structures under the conditions studied. The sedimentation the axis of rotation and co is the angular velocity. Sedimentation 
profiles are shown in Fig. 2. The slopes of these plots are equilibrium runs of all the proteins were carried out at a concentra- 
tion of ~ 1 mg/ml in 100 sodium phosphate, pH 6.6. Runs carried proport ional  to the molecular weights (Eq. 1). For  MCP-3 out at rotor speeds between 24000 and 32000 rpm depending on 
the profile is linear, indicative of the absence of higher order the sample for a period of 48 h. Molecular weights were calculated 
species. The observed MW of 8930 calculated from the slope from the slopes of the plot using Eq. 1. 
K.-S. Kim et al./FEBS Letters 395 (1996) 277-282 279 
Table 1 
Proton resonace assignments of MCP-3 at 30°C, pH 5.1 a'b 
Residue NH Call  CI3H Others 
Gln a 4.69 2.62, 2.09 CrH 2.44 
Pro 2 4.52 2.22, 1.89 CrH 2.01; C~H 3.58, 3.70 
Val 3 8.30 4.14 2.07 CVH3 0.97, 1.00 
Gly 4 8.47 3.98 
Ile 5 7.97 4.21 1.85 CVH 1.41, 1.16; CVH3 0.89; Call3 0.83 
Asn 6 8.52 4.81 2.91, 2.80 
Thr 7 8.18 4.35 4.28 CVH3 1.20 
Ser s 8.35 4.55 3.93, 3.88 
Thr 9 8.38 4.38 4.19 CVH3 1.15 
Thr 1° 8.24 4.34 4.14 CVH3 1.22 
Cys u 8.12 4.99 2.80, 2.54 
Cys 12 8.36 4.64 2.41, 2.72 
Tyr13 c 4.42 3.13, 2.72 C~H 7.11; C~H 6.77 
Arg 14 7.45 4.32 1.78, 1.66 CVH 1.50; C~H 3.20; Nell 7.18 
Phe 15 8.54 4.81 2.91, 3.23 C~H 7.01; C~H 7.20; C;H 7.11 
Ile 16 8.72 4.41 2.18 CVH 1.62, 1.73; CVH3 1.25; C6H3 1.05 
Asn 17 8.64 5.06 2.95 N~H2 7.64, 6.95 
Lys TM 7.39 4.29 1.71, 1.59 C~H 1.29 
Lys 10 7.71 2.52 1.16, 1.09 CVH 0.70, 0.90; C~H 1.35 
Ile 2° 6.14 4.32 1.64 CVH 1.47, 1.05; CYH3 0.84; C~H3 0.83 
Pro 2~ 4.37 2.35, 1.75 CVH 1.98 1.93; CSH 3.37, 3.78 
Lys 22 8.26 3.27 1.31, 1.13 CVH 0.63; C~H 0.85;C~H 1.03 
Gin 23 8.71 4.18 2.06 Cell 2.43, 2.37; N~H2 7.55, 6.89 
Arg 24 7.75 4.32 2.07, 1.78 CVH 1.66;C~H 3.13, 3.22; N~H 7.40 
Leu 25 7.50 4.34 1.92, 1.28 CVH 1.56; C~H3 0.28, 0.52 
Glu 26 9.15 4.65 1.93, 1.73 CVH 2.21 
Ser 27 8.08 4.81 4.02, 4.08 
Tyr 2s 8.62 5.74 2.42, 2.90 C~H 6.77, C~H 6.86 
Arg 29 8.59 4.59 1.84, 1.70 CVH 1.35; C~H 3.05, 3.17; NEH 7.54; NqH 6.88 
Arg 3° 8.86 5.18 1.73, 2.09 CVH 1.80, 1.65; C~H 3.27; Nell 7.44 
Thr zl 8.41 4.58 4.59 CVH3 1.24 
Thr 32 8.32 4.51 4.32 CVH3 1.21 
Ser 33 8.43 4.51 4.02, 3.91 
Ser 34 8.52 4.34 3.86 
His 35 8.13 4.69 3.11, 3.35 
Cys 36 7.68 5.17 2.68, 3.36 
Pro 37 4.38 2.42, 2.00 CVH 2.18, 2.08; CSH 3.90, 3.67 
Arg as 7.18 4.55 1.71, 1.90 CYH 1.53; Call 3.06; N~H 7.15 
Glu 39 8.63 4.08 1.94 CVH 2.31, 2.18 
Ala 4° 8.12 4.97 1.57 
Va141 8.42 4.46 1.36 C~Ha 0.60, 0.12 
Ile 42 8.99 4.94 1.62 CVH 1.41, 0.90; C3'H3 0.74; C8H3 0.65 
Phe 43 9.30 5.31 2.93, 3.13 C~H 7.24; CEH 6.91; C;H 7.26 
Lys 44 9.01 5.38 2.00, 1.85 CVH 1.40; C~H 1.64; Cell 2.95 
Thr 45 9.10 5.22 4.78 C7H3 1.22 
Lys 46 8.66 4.22 1.76, 2.03 C~H 1.40 
Leu 47 7.69 4.50 1.81, 1.56 CVH 1.59; Call3 0.93, 0.87 
Asp ~s 8.07 4.31 3.03, 2.68 
Lys 49 7.34 4.58 1.75, 1.84 C~H 1.31, C~H 1.44, Cell 3.01 
Glu ~° 8.49 5.47 2.43, 1.95 CVH 2.00, 1.80 
lie 5~ 9.17 4.54 1.95 C~H 1.23, 1.54; C~H3 1.12; C~H3 0.88 
Cys 5~ 8.86 5.07 3.48, 2.78 
Ala 53 9.85 4.99 1.32 
Asp 54 8.41 4.08 2.60, 1.64 
Pro ~5 3.99 1.94 CVH 1.72, 1.83; Call 4.01, 3.93 
Thr ~6 8.26 4.04 4.20 CVH3 1.18 
Gin ~7 7.44 4.21 1.65, 1.85 C~H 2.37, 2.23 
Lys 5s 8.77 3.77 1.94 CVH 1.48; Call 1.75, 1.65; Cell 3.05 
Trp 59 8.26 4.28 3.05, 2.98 C~H 7.58; N~H 10.06; C~3H 6.35; C~2H 7.38; C~3H 6.50; Cn~H 6.94 
Val 6° 5.71 2.79 1.78 CVH3 -0.67, 0.42 
Gin 6~ 7.20 3.97 2.14, 2.08 CVH 2.40, 2.28; N~H~ 6.62, 7.40 
Asp 62 8.64 4.44 2.89, 2.76 
Phe 63 8.60 4.56 3.54, 2.91 C~H 7.01; C~H 7.44; C~H 7.38 
Met 64 8.42 3.68 2.28, 2.11 CVH 1.77 0.61; Cell3 1.81 
Lys 65 7.64 4.14 1.98, 1.77 CVH 1.52; CaH 1.69; CaH~ 3.02 
His 66 7.89 4.40 3.43, 3.24 Ca2H 6.70; C~IH 7.22 
Leu 67 8.16 4.09 2.24, 1.76 C~H 2.01; C~H3 1.11, 0.85 
Asp 6s 8.63 4.60 2.90, 2.77 
Lys 69 7.60 4.21 1.86, 1.91 CVH 1.48; Call 1.58; C~H 3.02 
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Table 1 (continued) 
Residue NH Call CPH Others 
Lys 7° 7.89 4.28 1.91, 1.82 CYH 1.48; CSH 1.70; C~H 3.04 
Thr 71 7.97 4.35 4.28 CYH3 1.26 
Gin 72 8.21 4.43 2.03, 2.14 CYH 2.41 
Thr z3 8.20 4.59 4.17 CYH3 1.27 
Pro TM 4.43 2.31, 1.91 CYH 2.04; CSH 3.86, 3.73 
Lys 7~ 8.34 4.32 1.85, 1.75 CYH 1.46; C~H 1.70; C~H 3.02 
Leu 76 7.87 4.21 1.59 CYH 1.59; C5H3 0.86, 0.90 
~Uncertainities in chemical shift are _+ 0.02 ppm. 
~Gln-1 exists as a pyroglutamate. 
CNot seen. 
compared to MCP-3. The rotational correlation times were 30 structures were calculated using the program X-PLOR, 
calculated (Eq. 3) to be ~ 13 ns for MCP-1 and MCP-2 all of which displayed good covalent geometry and showed 
and ,~ 7 ns for MCP-3. Although absolute molecular weight minimal or no NOE violations. In these structures, there were 
cannot be calculated accurately from T2 values, the Zc values no NOE violations greater than 0.5 .~ and dihedral violations 
are appropriate for molecular weights of a dimer (,~ 18 000) greater than 5 °. The chemokine polypeptide fold consists of a 
and a monomer (,~ 9000), respectively [26]. The NMR solu- relatively undefined N-terminal region and 3-antiparallel [3- 
tion structure of MCP-1 has been solved recently [28] and was strands and a COOH-terminal a-helix crossing over the [3- 
shown to be a dimer which is consistent with the above re- sheet (Fig. 5). The first 9 residues at the N-terminus and 
sults, residues 70-76 in the C-terminus are undefined, and the ob- 
The NMR chemical shift assignments for MCP-3 was servation that the shifts of these spin systems resemble those 
achieved using standard two-dimensional NMR techniques of a random coil support the observation that these terminal 
(Table 1). Scalar connectivities were established from TOCSY residues are unstructured [29]. The rmsd of the backbone 
and DQF-COSY spectra and through-space connectivities atoms and heavy atoms for residues 11-68 are 0.75 and 1.4 
were identified from the NOESY spectra. The secondary A, respectively. Residues 11-22 are relatively less well defined 
structure of MCP-3, on the basis of the characteristic sequen- when compared to other chemokines which show a good de- 
tial, medium- and long-range NOEs involving Ca l l  and finition for these residues. The rest of the structure (residues 
amide protons is shown in Fig. 4. The pattern of NOE-de- 23 68) is well defined with an rmsd of 0.5 ,~ for the backbone 
rived intra-chain distances was similar to that of other chem- atoms and an rmsd of 1.1 A for the heavy atoms. 
okines indicating that it has a similar folded structure. How- It was observed that the tertiary fold of MCP-3 is very 
ever, no inter-chain NOEs were found, suggesting that MCP-3 similar to that of other CXC and CC chemokines. Fig. 6 
is a monomer, consistent with the Rz and the sedimentation shows an alignment of the backbone atoms of the most or- 
equilibrium studies. An examination of the chemical shifts of dered regions of MCP-3 with that of monomeric IL-8, a CXC 
the residues at the N-terminus howed that the shifts are close chemokine and MIP-1[3, a CC chemokine. 
to that expected for a random coil indicating that these resi- 
dues are not involved in dimer formation [29]. The corre- 4. Discussion 
sponding residues in MIP-I[3 and RANTES show chemical 
shifts which are characteristic of a [3 sheet [11,12]. Four lines of evidence indicate that MCP-3 does not have a 
propensity to dimerize and remains a monomer under a wide 
range of conditions. First, sedimentation equilibrium studies 
100 : 
showed that MCP-3 exists as a monomer up to 2 mg/ml. 
Second, calculation of the rotational correlation time from 
NMR indicates that MCP-3 remains a monomer up to con- 
o centrations of ~ 20 mg/ml. Third, the chemical shifts of the 
residues in the N-terminal region indicate that these residues 
. • MCP-1 ~_,, ~ .  ~ li°cs ' .~ ~ c~ 
o MCP-2 
l o -  ~; • MCP-3 
Y~o 
41 ,is 
0 
relaxation delay time (aec) 
Fig. 4. Schematic representation f the anti-parallel [~-sheet as deter- 
Fig. 3. Plot of the 1HNMR transverse relaxation of the CH3 reso- mined from the NOE connectivities. Observed intrastrand NOEs are 
nances of Val 6° in MCP-1, MCP-2 and MCP-3 as a function of dif- indicated by arrows and putative hydrogen bonds predicted from 
ferent delay times, the NOE data are denoted by broken lines. 
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ence in aggregation propensity of MCP-3 and MCP-2 is not 
responsible for the functional differences. Although MCP-2 is 
less potent than MCP-3, it seems unlikely that this is due to 
dimerization, because MCP-2 exists mostly as a monomer at 
functional concentrations. It is likely that multiple structural 
features contribute towards dimer formation, residues preced- 
ing the first cysteine at the N-terminus being most critical. 
~ Whereas the NMR solution structure indicated that MCP-1 
~ ~  ~ was a dimer [28], a MCP-1 analog (9-76), missing the first first % 
8 residues was found to be predominantly a monomer by 
sedimentation and NMR studies (data not shown). 
The folded structure of MCP-3 (Fig. 5) is similar to that of 
other chemokines representing both the CC and CXC sub- 
family. As expected from the greater sequence similarity and 
the common CC motif, the alignment of the backbone atoms 
was better with the CC chemokines. Thus, it has the charac- 
teristic hemokine fold: a disordered NH2 terminal region, the 
CC motif, an extended loop, 3 13 strands, and a COOH-ter- 
t minal c~ helix. The major difference in the structure between 
MCP-3 and known structures of other CC chemokines, MCP- 
1, RANTES and MIP-113, was in the NH2-terminal region. 
The entire NH2-terminal region in MCP-3 was disordered and 
suggests an intrinsic flexibility whereas the corresponding re- 
gion is structured in MCP-1, RANTES and MIP-113. This 
region of the protein has been shown to play a role in CXC 
chemokines for differential binding to the two receptors in 
Fig. 5. Schematic showing the minimized average NMR structure of neutrophils [6]. Future studies involving mutagenesis and 
MCP-3. The figure was created using the program MOLSCRIPT synthesis of chimeric proteins should reveal the relevance of 
[33]. this structural flexibility for function. 
MCP-3 is the first chemokine reported which remains 
monomeric to concentrations used in structural determina- 
tions (,~ 20 mg/ml). 1-309, a CC chemokine, has shown to 
are unstructured. Fourth, detailed analysis of the NOEs re- be a monomer at sedimentation concentrations [30] and the 
vealed no NOEs which can be attributed to inter-chain inter- Ko of IL-8 [30,31] and MCP-1 [30] has been shown to be in 
actions. This is significant because the tertiary structures of all the laM range. The in vitro functional response of a mono- 
known chemokines to date, including three CC chemokines, meric IL-8 which cannot dimerize was shown to be indistin- 
are dimers or tetramers, guishable from that of the native protein [32]. 
Sedimentation studies howed that both MCP-1 and MCP- The results suggest hat MCP-1, MCP-2 and MCP-3 nor- 
2 are in a monomer-dimer quilibrium in the 0.2 2 mg/ml mally function as monomers and that dimerization is not es- 
concentration range. As the functional concentration is at sential for receptor binding and activation in vitro. It remains 
least 3 log units lower, these proteins are monomeric at the to be determined whether dimerization is critical in vivo for 
functional concentrations which is consistent with a previous factors that has not yet been examined. It is believed that it is 
sedimentation study of MCP-1 [30]. The MCP-2 used in these the heparin bound chemokines which bind to the receptor and 
experiments has been shown to have the same spectrum of whether dimerization is essential for heparin binding remains 
functional activities as MCP-3. This suggests that the differ- to be investigated. 
Fig. 6. Comparison of MCP-3 (thick black) with MIP-113 (thick gray) and monomeric IL-8 (thin black). The best-fit superpositions of the back- 
bone atoms are shown. 
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